Found 15 clinical trials
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) (INTRAGO-II)
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.
- 0 views
- 20 Jul, 2022
- 17 locations
Supramarginal Resection in Glioblastoma
Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only 10 months.
- 0 views
- 16 Feb, 2024
- 19 locations
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved …
- 0 views
- 16 Feb, 2024
- 1 location
Niraparib/TTFields in GBM
Evaluating the efficacy and safety of niraparib and Tumor-Treating Fields (TTFields) in recurrent glioblastoma (GBM).
- 0 views
- 16 Feb, 2024
- 1 location
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Background Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help.
- 0 views
- 16 Feb, 2024
- 1 location
Infigratinib in Recurrent Glioblastoma Patients
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20 participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total of 20 participants will be enrolled into the proposed …
- 0 views
- 05 Aug, 2020
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial.
- 0 views
- 05 Aug, 2020
Evaluation of GLR2007 for Advanced Solid Tumors
This study is designed to determine the safety, tolerability, and optimal dosing of GLR2007 in participants with advanced solid tumors that do not respond well to standard clinical therapies.
- 0 views
- 16 Feb, 2024
- 4 locations
Anterior Temporal Lobectomy in Temporal Glioblastoma (ATLAS/NOA-29)
If proven superior to GTR, ATL could emerge as the preferred surgical strategy for isolated temporal lobe glioblastoma, offering robust evidence in favor of extending supramarginal resection principles to the broader context of glioblastoma care.
- 0 views
- 14 Jun, 2025
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM). All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease.
- 0 views
- 16 Feb, 2024
- 3 locations
- 1
- 2